Hansa Biopharma
HNSA · Nasdaq Stockholm
Public Market Listing
Live quotes, historical charts, and market capitalization for Hansa Biopharma are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Imlifidase(Idefirix) | Phase 3 | Immunoglobulin G (IgG), all four human subclassesProtein / enzyme therapeutic | Chronic Kidney Disease |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(6)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (2)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $3.8M | $6.3M | $71M | $21M | report ↗ |
View 1 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | $3.2M | $7.4M | $27M | $16M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $23M | $31M | $76M | $54M | report ↗ |
Hansa Biopharma reported full-year 2025 revenue of $22.71M, up 40.2% YoY, with R&D spend of $31.13M, down 12.4% YoY, and cash and equivalents of $76.22M. Net income or loss was not disclosed, while quarterly net burn was reported at $54.08M.
The company highlighted its December submission of a Biologics License Application to the FDA for imlifidase in highly sensitized kidney transplant patients, with Priority Review requested and a potential PDUFA date in August 2026. Initial data from the GNT-018-IDES trial showed imlifidase removed AAV antibodies without severe side effects, and the next-generation enzyme HNSA-5487 is being advanced in Guillain-Barré syndrome with FDA interactions planned for the first half of 2026. Hansa also completed a directed share issue raising 671.5 MSEK (~$71.3M).